Neal D. Shore, MD, presented “29 MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate Biopsies” during the 29th Annual International Prostate Cancer Update on January 26, 2019 in Beaver Creek, Colorado.

How to cite: Shore, Neal D. “29 MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate Biopsies” January 26, 2019. Accessed Jul 2024.

29 MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate Biopsies- Summary:

Neal D. Shore, MD, reviews a novel 29 MHz high-resolution micro-ultrasound system with improved visualization for prostate biopsy compared to the current standard. He also provides a brief overview of current clinical evidence for this technology.


Systematic sextant or 12-core biopsy has not proven to be the most accurate test for identifying prostate cancer. The advent of an ultrasound-guided technique did improve biopsy accuracy as compared to digitally-guided biopsy. Even so, transrectal ultrasound (TRUS) biopsy is an invasive procedure with a burden of sepsis risk that only reduces the risk of prostate cancer by a third. While TRUS was an improvement from past techniques, its limitations leave room for new generational advancements.

Utilizing a novel 29 MHz high-resolution micro-ultrasound system for more accurately targeting biopsies may satisfy these unmet needs. The system allows for improved visualization of prostatic and peripheral zone margins, textural changes in tissue, and prior biopsy needle tracks up to 50mm deep in the prostate.  

This technology operates within a standard urologic workflow, as it utilizes a gradation system similar to PI-RADS called “prostate risk identification using micro-ultrasound” (PRI-MUS), and is consistent with TRUS preparation and technique. Therefore, practicing urologists conditioned to the TRUS procedure can easily adapt to this technique. A physician can become proficient with this technology utilizing its built-in software with no additional coursework. According to a report by Hyndman et al., a physician can generally master biopsy performance with this technology after 15 cases.

About the International Prostate Cancer Update

The International Prostate Cancer Update (IPCU) is an annual, multi-day CME conference focused on prostate cancer treatment updates. The conference’s faculty consists of international experts, and the event caters to urologists, medical oncologists, radiation oncologists, and other healthcare professionals. Topics encompass prostate cancer management, from diagnosis to treating advanced and metastatic disease. Dr. Shore presented this lecture during the 29th IPCU in 2019. Please visit this page in order to learn more about future IPCU meetings.


Neal D. Shore, MD, FACS, graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center and is the Chief Medical Officer, Strategic Growth and Pharmacy, GenesisCare, US.

Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored or coauthored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network, Maple Tree Alliance, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy for the Large Urology Group Practice Association (LUGPA) Specialty Network. He also co-chairs the annual AUA International Prostate Forum. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP and World Journal of Urology, and he also serves as an editor of Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.